A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] ...

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...

NICE’s healthtech guidance provided me with the perfect catalyst for change.

There is a simple discount patient access scheme for tisotumab vedotin. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact Genmab at ...

Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults. This guidance updates and replaces NICE technology ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update) In development GID-NG10450 Expected publication date: ...